Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome Inc. chief business officer Horn Kinney reported an option exercise and share sale. On the same day, Kinney exercised employee stock options to acquire 1,092 shares of common stock at $12.92 per share and sold 1,092 shares at $25.00 per share in an open-market transaction.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following these transactions, Kinney reported no directly held common shares and 128,908 employee stock options remaining, exercisable at $12.92 and expiring on August 8, 2034.
Immunome Inc. director Isaac Barchas reported that an entity associated with him, AMBHMC II LLC, sold a total of 100,000 shares of Immunome common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
The sales occurred on July 6 and July 7, 2026, at weighted average prices of about $24.11 and $24.20 per share across specified price ranges. After these transactions, filings show 108,504 shares held indirectly and 103,259 shares held directly. Barchas disclaims beneficial ownership of the LLC-held shares beyond any pecuniary interest.
Robert Lechleider, Chief Medical Officer of Immunome, exercised stock options for 55,000 shares of common stock at $8.73 per share on July 2, 2026, then sold 55,000 shares in three tranches at weighted average prices of $21.95, $22.76 and $23.44 per share under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following these transactions, he directly holds 15,805 shares of common stock.
IMNM files Form 144 reporting intended sale of Common Stock by affiliates. The filing lists multiple planned or recent transactions totaling specific share amounts: 100,000 shares reported as "Securities To Be Sold" (private placement proceeds listed as Cash) with an original issuance date of 10/03/2023. The excerpt also shows recent sales by affiliates: two entries of 100,000 shares with trade dates 06/30/2026 and 07/02/2026, and an additional affiliate sale of 1,050 shares on 06/30/2026.
Immunome Inc. reported insider sales by entities associated with director Isaac Barchas. On June 30 and July 2, 2026, ABHMC II LLC and Arsenal Bridge Venture II-B LLC completed open‑market sales totaling 201,050 shares of Immunome common stock under pre‑arranged Rule 10b5‑1 trading plans.
The filing shows weighted average sale prices of $21.12, $22.35, and $23.33 across the three reported transactions. After these sales, entities associated with Barchas held 208,504 shares indirectly, while Barchas’s direct holdings were reported at 103,259 shares. He disclaims beneficial ownership beyond any pecuniary interest.
IMNM reports sales of Common Stock under Rule 144-style disclosures. The excerpt lists a 100,000 share block associated with a private placement dated 10/03/2023, and records secondary transactions on 06/30/2026 by ABHMC II LLC (100,000 shares) and Arsenal Bridge Venture II-B LLC (1,050 shares, proceeds $22,180.72).
The issuer filed a Form 144 notice for the proposed sale of 55,000 shares of Common Stock acquired by stock option exercise and to be sold by Fidelity Brokerage Services LLC on 07/02/2026. The filing shows a related prior sale of 55,000 shares on 06/25/2026 for $1,091,673.00.